Trends in hepatitis C virus coinfection and its cascade of care among adults living with HIV in Asia between 2010 and 2020

Jeremy Ross; Dhanushi Rupasinghe; Anchalee Avihingsanon; Man Po Lee; Sanjay Pujari; Gerald Sharp; Nagalingeswaran Kumarasamy; Suwimon Khusuwan; Vohith Khol; I. Ketut Agus Somia; Thach Ngoc Pham; Sasisopin Kiertiburanakul; Jun Yong Choi; Cuong Duy Do; Annette H. Sohn; Awachana Jiamsakul; on behalf of the TAHOD-LITE study group of IeDEA Asia‐Pacific

doi:10.1371/journal.pone.0287909

Peer Review History

Original SubmissionFebruary 16, 2023
27 Mar 2023 Decision Letter - Chen-Hua Liu, Editor PONE-D-23-04685Trends in hepatitis C virus coinfection and its cascade of care among adults living with HIV in Asia between 2010 and 2020PLOS ONE Dear Dr. Ross, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by May 11 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Chen-Hua Liu Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating the following in the Competing Interests section: "AHS has received grants to her institution from ViiV Healthcare and Gilead Sciences. Other authors have declared that no competing interests exist. " Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf. 3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. 4. One of the noted authors is a group or consortium " TAHOD-LITE study group of IeDEA Asia‐Pacific". In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address. 5. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. 6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly ******** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes ****** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes ****** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes ****** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This study from a prospective observational cohort of the International Epidemiology Databases to Evaluate AIDS (IeDEA) Asia-Pacific (TAHOD-LITE) was aimed to assessed regional HCV coinfection and cascade outcomes among adults living with HIV in care from 2010-2020 in Asia. 1. The proportion of people living with HIV (PLHIV) with a positive anti-HCV test was reported over three time periods that broadly correspond to very limited DAA access (the pre-DAA era), initial DAA access, and expanded DAA access in the Asia-Pacific region: 2010-2014, 2015-2017, and 2018-2020. Results of three time periods should be mentioned in Abstract. 2. Liver fibrosis, liver function reserve, renal function, HCV genotype and HCV RNA may be factors associated with chronic HCV treatment response. The proportion of liver cirrhosis, liver fibrosis grade, serum albumin, creatine, HCV genotype and HCV RNA should be analyzed in Table 4. 3. Table 2, Calendar year, “2017”-2020 should be “2018”-2020. ****** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No ******** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. https://doi.org/10.1371/journal.pone.0287909.r001
Revision 1
28 Apr 2023 Author Response Responses to reviewer and editor comments have been provided in the attached cover letter and response to reviewers letter. These are also included below. Academic editor comments and responses Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. Response: We have reviewed and confirm that our manuscript meets PLOS ONE's style requirements, including those for file naming. Thank you for stating the following in the Competing Interests section: "AHS has received grants to her institution from ViiV Healthcare and Gilead Sciences. Other authors have declared that no competing interests exist.” Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: "This does not alter our adherence to PLOS ONE policies on sharing data and materials.” Response: We have updated our Competing Interests section to include the above statement and provided it in the revised cover letter, as requested. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. Response: We have provided the ethical or legal restrictions on sharing our de-identified data set in the revised cover letter, as requested. One of the noted authors is a group or consortium "TAHOD-LITE study group of IeDEA Asia‐Pacific". In addition to naming the author group, please list the individual authors and affiliations within this group in the acknowledgments section of your manuscript. Please also indicate clearly a lead author for this group along with a contact email address. Response: The individual authors for this group and their affiliations have been provided. We indicated a lead author for this group and their contact email address in the revised manuscript, as requested. Please include your full ethics statement in the ‘Methods’ section of your manuscript file. In your statement, please include the full name of the IRB or ethics committee who approved or waived your study, as well as whether or not you obtained informed written or verbal consent. If consent was waived for your study, please include this information in your statement as well. Response: We have replaced the previous ethics statement with the following full ethics statement that includes the above information, in the ‘Methods’ section of our manuscript, as requested: “The following IRBs approved the study: Cambodia Ministry of Health National Ethics Committee for Health Research; Kowloon Central / Kowloon East Research Ethics Committee; VHS Institutional Ethics Committee; Institutional Ethics Committee Rao Nursing Home; Kerti Praja Foundation IRB; Severance Hospital Yonsei University College of Medicine IRB; The Ethical Committee for Research in Human Subject, Chiangrai Prachanukroh Hospital; Institutional Review Board Faculty of Medicine, Chulalongkorn University; Committee on Human Rights Related to Research Involving Human Subjects, Faculty of Medicine Ramathibodi Hospital; Hanoi School of Public Health IRB; The Ethical Review Board for Biomedical Research of National Hospital of Tropical Diseases; UNSW Human Research Ethics Committee; and Advarra IRB. Written informed consent was obtained at the following study sites: Chiangrai Prachanukroh Hospital; HIV-NAT, the Thai Red Cross AIDS Research Centre; and Ramathibodi Hospital. Consent at all other sites was waived due to the observational nature of the study, and because data was only collected retrospectively from available medical records.” Please review your reference list to ensure that it is complete and correct. Response: We have reviewed the reference list and confirm it is complete and correct. Reviewer #1 comments and responses Overall: This study from a prospective observational cohort of the International Epidemiology Databases to Evaluate AIDS (IeDEA) Asia-Pacific (TAHOD-LITE) was aimed to assess regional HCV coinfection and cascade outcomes among adults living with HIV in care from 2010-2020 in Asia. Response: Thank you for your review of our manuscript and recommendations to improve it. We hope these have been adequately addressed in our responses (below) and associated edits. Comment 1. The proportion of people living with HIV (PLHIV) with a positive anti-HCV test was reported over three time periods that broadly correspond to very limited DAA access (the pre-DAA era), initial DAA access, and expanded DAA access in the Asia-Pacific region: 2010-2014, 2015-2017, and 2018-2020. Results of three time periods should be mentioned in Abstract. Response: We have added data on the positive anti-HCV test results and HCV cascade proportions from all three of the 2010-2014, 2015-2017, and 2018-2020 time periods to the abstract. Comment 2. Liver fibrosis, liver function reserve, renal function, HCV genotype and HCV RNA may be factors associated with chronic HCV treatment response. The proportion of liver cirrhosis, liver fibrosis grade, serum albumin, creatinine, HCV genotype and HCV RNA should be analyzed in Table 4. Response: Thank you for this suggestion to include these additional factors in the chronic HCV treatment response regression analysis. As suggested we did have adequate creatinine data and have added that to the analysis. However, we were either unable to include the other factors or felt it could confuse the findings. We believe that associations between liver cirrhosis and fibrosis and chronic HCV treatment response are likely already covered to an extent by our inclusion of ALT and AST levels. Unfortunately, we did not collect albumin test results from our study participants so cannot add that to the regression analysis. In addition, HCV genotype results are very limited or often not available, particularly from sites in resource-limited countries or countries that use pan-genotypic DAAs and rarely test HCV genotype. Regarding HCV RNA, we expect more HCV RNA testing to be done in later calendar years which would confound with the calendar year variable included. Therefore, instead of including it, HCV RNA has been discussed. Furthermore, inclusion of HCV RNA in our analysis will likely show that high HCV RNA is associated with a reduced hazard for achieving SVR. Table 4 and the associated text in the methods and results sections have been revised to reflect the changes that were made. Comment 3. Table 2, Calendar year, “2017”-2020 should be “2018”-2020. Response: Thank you for spotting this error, which we have now corrected. Attachments Attachment Submitted filename: Response to reviewers.doc https://doi.org/10.1371/journal.pone.0287909.r002
31 May 2023 Decision Letter - Chen-Hua Liu, Editor PONE-D-23-04685R1Trends in hepatitis C virus coinfection and its cascade of care among adults living with HIV in Asia between 2010 and 2020PLOS ONE Dear Dr. Ross, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please ensure that your decision is justified on PLOS ONE’s publication criteria and not, for example, on novelty or perceived impact. Please submit your revised manuscript by Jul 15 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Chen-Hua Liu Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments (if provided): * Please make a brief discussion about the potential HCV reinfection among PLWH after achieving SVR with antiviral treatment. In Taiwan, a recent study showed that a increasing trend of HCV reinfection among HIV positive patients after the commencement of direct-acting antivirals, which may post a public health treat and should alert the physicians about the post-treatment surveillance based on public health perspectives (Liu CH, et al. Open Forum Infect Dis 2022). [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed ******** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes ****** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes ****** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes ****** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes ****** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: All comments have been addressed. ****** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No ******** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. https://doi.org/10.1371/journal.pone.0287909.r003
Revision 2
13 Jun 2023 Author Response Additional editor comments: Please make a brief discussion about the potential HCV reinfection among PLWH after achieving SVR with antiviral treatment. In Taiwan, a recent study showed that a increasing trend of HCV reinfection among HIV positive patients after the commencement of direct-acting antivirals, which may post a public health treat and should alert the physicians about the post-treatment surveillance based on public health perspectives (Liu CH, et al. Open Forum Infect Dis 2022). Response: Thank you for the suggestion to add to the discussion the potential for HCV reinfection and the importance of post HCV treatment surveillance among those living with HIV, and for providing an associated reference. The following text was added to the discussion section: “Improved HCV screening and scale-up of HCV treatment are also important for reducing the risk of HCV re-infection amongst PLHIV (56). A recent study of HCV re-infection among an adult PLHIV cohort in Taiwan found that those living with HIV had higher HCV re-infection rates than the HIV-negative reference population, and that HCV reinfection incidence increased following the availability of DAAs in the country, further highlighting the importance of post HCV treatment surveillance among PLHIV (57).” The following references were also added: “56. Hosseini-Hooshyar S, Hajarizadeh B, Bajis S, Law M, Janjua NZ, Fierer DS, et al. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression. The lancet HIV. 2022;9(6):e414-e27” and “57. Liu CH, Sun HY, Peng CY, Hsieh SM, Yang SS, Kao WY, et al. Hepatitis C Virus Reinfection in People With HIV in Taiwan After Achieving Sustained Virologic Response With Antiviral Treatment: The RECUR Study. Open Forum Infect Dis. 2022;9(8):ofac348.” Attachments Attachment Submitted filename: Response to reviewers.doc https://doi.org/10.1371/journal.pone.0287909.r004
15 Jun 2023 Decision Letter - Chen-Hua Liu, Editor Trends in hepatitis C virus coinfection and its cascade of care among adults living with HIV in Asia between 2010 and 2020 PONE-D-23-04685R2 Dear Dr. Ross, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Chen-Hua Liu Academic Editor PLOS ONE https://doi.org/10.1371/journal.pone.0287909.r005
Formally Accepted
21 Jun 2023 Acceptance Letter - Chen-Hua Liu, Editor PONE-D-23-04685R2 Trends in hepatitis C virus coinfection and its cascade of care among adults living with HIV in Asia between 2010 and 2020 Dear Dr. Ross: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Chen-Hua Liu Academic Editor PLOS ONE https://doi.org/10.1371/journal.pone.0287909.r006

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .